1. Home
  2. RGC vs IPHA Comparison

RGC vs IPHA Comparison

Compare RGC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGC
  • IPHA
  • Stock Information
  • Founded
  • RGC 2014
  • IPHA 1999
  • Country
  • RGC Hong Kong
  • IPHA France
  • Employees
  • RGC N/A
  • IPHA N/A
  • Industry
  • RGC Medicinal Chemicals and Botanical Products
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • RGC Health Care
  • IPHA Health Care
  • Exchange
  • RGC Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • RGC 105.3M
  • IPHA 148.3M
  • IPO Year
  • RGC 2021
  • IPHA 2019
  • Fundamental
  • Price
  • RGC $4.86
  • IPHA $1.79
  • Analyst Decision
  • RGC
  • IPHA Strong Buy
  • Analyst Count
  • RGC 0
  • IPHA 1
  • Target Price
  • RGC N/A
  • IPHA $11.50
  • AVG Volume (30 Days)
  • RGC 8.8K
  • IPHA 779.8K
  • Earning Date
  • RGC 10-25-2024
  • IPHA 09-12-2024
  • Dividend Yield
  • RGC N/A
  • IPHA N/A
  • EPS Growth
  • RGC N/A
  • IPHA N/A
  • EPS
  • RGC N/A
  • IPHA N/A
  • Revenue
  • RGC N/A
  • IPHA $36,202,722.00
  • Revenue This Year
  • RGC N/A
  • IPHA N/A
  • Revenue Next Year
  • RGC N/A
  • IPHA $101.65
  • P/E Ratio
  • RGC N/A
  • IPHA N/A
  • Revenue Growth
  • RGC N/A
  • IPHA N/A
  • 52 Week Low
  • RGC $3.03
  • IPHA $1.29
  • 52 Week High
  • RGC $32.44
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • RGC 44.96
  • IPHA 45.92
  • Support Level
  • RGC $4.75
  • IPHA $1.64
  • Resistance Level
  • RGC $5.21
  • IPHA $1.87
  • Average True Range (ATR)
  • RGC 0.30
  • IPHA 0.12
  • MACD
  • RGC 0.04
  • IPHA -0.04
  • Stochastic Oscillator
  • RGC 23.87
  • IPHA 28.66

About RGC Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: